Zydus Lifesciences and Sun Pharma have entered into a licensing agreement to co-market the innovative drug Desidustat in India for the treatment of anemia associated with chronic kidney disease (CKD). Zydus, which initially launched the drug as Oxemia in 2022, will continue marketing it domestically. Sun Pharma will market the drug under the brand name Rytstat. The partnership aims to provide a more accessible and convenient therapeutic option, reducing reliance on injectable medications. CKD affects over 115 million people in India, and Desidustat offers a convenient oral alternative to injectable treatments, improving the quality of life for patients.